244 related articles for article (PubMed ID: 31851576)
1. Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward.
Palwe S; Khobragade K; Kharat AS
Microb Drug Resist; 2020 Jun; 26(6):637-651. PubMed ID: 31851576
[TBL] [Abstract][Full Text] [Related]
2. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.
Papp-Wallace KM
Expert Opin Pharmacother; 2019 Dec; 20(17):2169-2184. PubMed ID: 31500471
[No Abstract] [Full Text] [Related]
3. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of newer β lactams/ β lactamase inhibitors for treatment of multidrug resistant gram negative infections in burn patients.
Gupta K; Dash S
Burns; 2019 Nov; 45(7):1725-1726. PubMed ID: 31445712
[No Abstract] [Full Text] [Related]
5. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Kaye KS; Pogue JM
Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
[TBL] [Abstract][Full Text] [Related]
6. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.
Veeraraghavan B; Pragasam AK; Bakthavatchalam YD; Anandan S; Ramasubramanian V; Swaminathan S; Gopalakrishnan R; Soman R; Abraham OC; Ohri VC; Walia K
Indian J Med Microbiol; 2018; 36(3):334-343. PubMed ID: 30429384
[TBL] [Abstract][Full Text] [Related]
7.
Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
[TBL] [Abstract][Full Text] [Related]
8. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Hsueh PR; Chen WH; Luh KT
Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
[TBL] [Abstract][Full Text] [Related]
9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.
MacVane SH
J Intensive Care Med; 2017 Jan; 32(1):25-37. PubMed ID: 26772199
[TBL] [Abstract][Full Text] [Related]
11. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
13. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
Bush K
Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
[TBL] [Abstract][Full Text] [Related]
14. Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms.
Kois AK; Nicolau DP; Kuti JL
Curr Opin Infect Dis; 2020 Dec; 33(6):482-494. PubMed ID: 33009141
[TBL] [Abstract][Full Text] [Related]
15. Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations?
Gatti M; Virgili G; Viale P; Pea F
Int J Antimicrob Agents; 2024 Jun; 63(6):107177. PubMed ID: 38643849
[No Abstract] [Full Text] [Related]
16. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
17. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
Guervil DJ; Chau T
Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
[TBL] [Abstract][Full Text] [Related]
18. Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.
Garcia-Bustos V; Cabañero-Navalón MD; Salavert Lletí M
Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):1-15. PubMed ID: 36193979
[TBL] [Abstract][Full Text] [Related]
19. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].
Probst-Kepper M; Geginat G
Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
D'Angelo RG; Johnson JK; Bork JT; Heil EL
Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
